Loading articles...
MASH (metabolic dysfunction-associated steatohepatitis) is a complex disease, and while we've made strides, key mechanistic details remain elusive. This demands a sharper focus on translational studies that can directly inform clinical practice.
A new study investigates the systemic and gut microbiome changes associated with metformin and liraglutide treatment in adolescents with type 2 diabetes. The findings offer potential insights into gastrointestinal side effects and treatment choices.
A new review in Nature Reviews Gastroenterology & Hepatology clarifies the complex interplay of metabolism, inflammation, and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). This understanding translates to practical guidance for risk s...
SGLT2 inhibitors show potential for managing glycemic control in Prader-Willi Syndrome, but clinicians must be vigilant about the risk of renal complications. This necessitates careful patient selection and close monitoring of kidney function throughout tre...
Youth-onset type 2 diabetes (T2D) poses unique challenges, and this study sheds light on how common treatments like metformin and liraglutide impact the gut microbiome. Understanding these shifts may allow for more targeted therapies and improved outcomes i...
Adolescent obesity and type 2 diabetes represent a growing crisis, often resistant to conventional treatments. This case report suggests that Mazdutide, a GLP-1/GCGR dual agonist, may offer a novel therapeutic avenue for these complex patients, but the find...
Patients with Prader-Willi Syndrome (PWS) face unique metabolic challenges; SGLT2 inhibitors may offer some benefit, but careful monitoring is essential. This analysis highlights the need for rigorous trials to define the risk-benefit profile of SGLT2 inhib...
A recent case report suggests that mazdutide, a GLP-1/GCGR dual agonist, may offer a promising treatment avenue for adolescents grappling with the complex interplay of obesity, type 2 diabetes, and hyperuricemia. However, the findings from a single case nec...
Patients with Prader-Willi Syndrome (PWS) present unique challenges when considering SGLT2 inhibitors due to their metabolic and behavioral complexities. Vigilant monitoring for euglycemic DKA and proactive management of dehydration risks are paramount when...
A single case report highlights the potential of mazdutide, a GLP-1/GCGR dual agonist, in treating a teenager with severe obesity and type 2 diabetes. However, clinicians should be aware that this is very early data with unknown long-term safety implication...